Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

4134

Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma

June 12, 2017
  • Bryant Furlow

In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.

  • READ >>
  • Add new comment

Carfilzomib Associated With Cardiotoxicity Risk in Multiple Myeloma

June 11, 2017
  • Bryant Furlow

Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.

  • READ >>
  • Add new comment

Isatuximab Combination Safe, Active for Relapsed, Refractory Myeloma

June 9, 2017
  • Leah Lawrence

The combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide/dexamethasone had an acceptable and manageable safety profile in patients with relapsed or refractory multiple myeloma.

  • READ >>
  • Add new comment

GPS Immunization for Multiple Myeloma Is Well Tolerated

June 8, 2017
  • Bryant Furlow

Among high-risk multiple myeloma patients, post-ASCT immunization with the Wilms tumor 1 peptide mixture galinpepimut-S is well tolerated and is associated with promising progression-free survival.

  • READ >>
  • Add new comment

Daratumumab Plus Standard of Care Well Tolerated in Multiple Myeloma

June 7, 2017
  • Bryant Furlow

Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.

  • READ >>
  • Add new comment

Insights Into the Appropriate Use of New Antimyeloma Therapies

January 15, 2017
  • Jonathan L. Kaufman, MD
  • Sagar Lonial, MD

Unfortunately, while survival outcomes with novel therapies have improved, the fraction of patients with multiple myeloma who are cured of their disease remains low. Immune therapies offer the hope for further improvement in outcomes and higher rates of cure.

  • READ >>
  • Add new comment

Reducing Zoledronic Acid Frequency Did Not Raise Risk of Skeletal Events

January 6, 2017
  • Dave Levitan

Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks.

  • READ >>
  • Add new comment

POINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

August 16, 2016
  • Nitya Nathwani, MD
  • Amrita Y. Krishnan, MD

Results of important studies addressing the optimal consolidation regimen and choice and duration of maintenance therapy are eagerly awaited, but it is evident that ASCT is imperative in the treatment of younger patients with multiple myeloma.

  • READ >>
  • Add new comment

COUNTERPOINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

August 16, 2016
  • Paul G. Richardson, MD

Myeloma is clearly not one disease but several. In terms of treatment choices, it is increasingly evident that one size of treatment does not fit all. Moreover, as therapy is tailored to each individual patient, with the ability to mobilize and collect stem cells and retain them after successful induction/remission therapy, younger patients have choices.

  • READ >>
  • Add new comment

Evolving M-Protein, Hemoglobin Identified Ultra-High-Risk Smoldering Myeloma

June 10, 2016
  • Leah Lawrence

Researchers were able to identify a subset of patients with smoldering multiple myeloma who have a greater than 80% risk of progressing to myeloma within 2 years.

  • READ >>
  • Add new comment

Pages

  • 1
  • 2
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".